The Claim
In heart transplant recipients, PCSK9 inhibitor therapy is associated with a low incidence of serious adverse drug reactions, and no events were attributed to the medication during follow-up of up to 21 months in a cohort of 97 patients.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who got a new heart and took a drug called a PCSK9 inhibitor didn’t have serious side effects from the medicine — in fact, none of the 97 patients studied had problems caused by the drug over nearly two years.
See the scientific wording
PCSK9 inhibitor therapy in heart transplant recipients is associated with a low incidence of serious adverse drug reactions, with no reported events attributed to the medication across 97 patients followed for up to 21 months.
What the research says
1 studyThe study looked at the same medicine in the same group of patients and found no serious side effects from the drug, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.